Trial Profile
A Multicenter, Uncontrolled, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Perampanel as Substitute for Oral Tablet in Subjects With Partial Onset Seizures (Including Secondarily Generalized Seizures) or Primary Generalized Tonic-clonic Seizures
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Perampanel (Primary) ; Antiepileptic drugs; Perampanel
- Indications Epilepsy; Partial epilepsies; Seizures; Tonic-clonic epilepsy
- Focus Adverse reactions
- Sponsors Eisai Inc
- 08 Dec 2020 Results assessing safety, pharmacokinetics and efficacy of intravenous formulation of Perampanel in patients with epilepsy, presented at the 74th Annual Meeting of the American Epilepsy Society
- 30 Nov 2020 According to an Eisai Co Ltd media release, data from this study will be presented at the 74th American Epilepsy Society Annual Meeting (AES2020), to be held virtually from December 4 to 8, 2020.
- 21 Jan 2020 Status changed from recruiting to completed.